Previous close | 10,290.00 |
Open | 10,236.00 |
Bid | 10,230.00 x 0 |
Ask | 10,232.00 x 0 |
Day's range | 10,204.00 - 10,248.00 |
52-week range | 9,461.00 - 12,392.00 |
Volume | |
Avg. volume | 2,951,774 |
Market cap | 158.679B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 34.22 |
EPS (TTM) | 2.99 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.28 (2.21%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 122.07 |
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal is AstraZeneca's second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday.
(Reuters) -AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal is AstraZeneca's second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday.
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.